| Year |
Citation |
Score |
| 2024 |
Bychkov I, Deneka A, Topchu I, Pangeni R, Ismail A, Lengner C, Karanicolas J, Golemis E, Makhov P, Boumber Y. Musashi-2 (MSI2) regulation of DNA damage response in lung cancer. Research Square. PMID 38659828 DOI: 10.21203/rs.3.rs-4021568/v1 |
0.358 |
|
| 2024 |
Topchu I, Bychkov I, Roshchina E, Makhov P, Boumber Y. PIP4K2B Protein Regulation by NSD1 in HPV-Negative Head and Neck Squamous Cell Carcinoma. Cancers. 16. PMID 38539515 DOI: 10.3390/cancers16061180 |
0.379 |
|
| 2024 |
Topchu I, Bychkov I, Gursel D, Makhov P, Boumber Y. NSD1 supports cell growth and regulates autophagy in HPV-negative head and neck squamous cell carcinoma. Cell Death Discovery. 10: 75. PMID 38346948 DOI: 10.1038/s41420-024-01842-6 |
0.337 |
|
| 2023 |
Topchu I, Bychkov I, Gursel D, Makhov P, Boumber Y. NSD1 supports cell growth and regulates autophagy in HPV-negative head and neck squamous cell carcinoma. Biorxiv : the Preprint Server For Biology. PMID 37786686 DOI: 10.1101/2023.09.19.558537 |
0.335 |
|
| 2023 |
Bychkov I, Deneka A, Topchu I, Pangeni RP, Lengner C, Karanicolas J, Golemis EA, Makhov P, Boumber Y. Musashi-2 (MSI2) regulation of DNA damage response in lung cancer. Biorxiv : the Preprint Server For Biology. PMID 37398283 DOI: 10.1101/2023.06.13.544756 |
0.341 |
|
| 2023 |
Bychkov I, Topchu I, Makhov P, Kudinov A, Patel JD, Boumber Y. Regulation of VEGFR2 and AKT Signaling by Musashi-2 in Lung Cancer. Cancers. 15. PMID 37173995 DOI: 10.3390/cancers15092529 |
0.318 |
|
| 2023 |
Bychkov I, Topchu I, Makhov P, Kudinov A, Patel JD, Boumber Y. Regulation of VEGFR2 and AKT signaling by Musashi-2 in lung cancer. Biorxiv : the Preprint Server For Biology. PMID 37034813 DOI: 10.1101/2023.03.29.534783 |
0.328 |
|
| 2022 |
Khaddour K, Felipe Fernandez M, Khabibov M, Garifullin A, Dressler D, Topchu I, Patel JD, Weinberg F, Boumber Y. The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer. Cancers. 14. PMID 36358724 DOI: 10.3390/cancers14215305 |
0.34 |
|
| 2022 |
Topchu I, Pangeni RP, Bychkov I, Miller SA, Izumchenko E, Yu J, Golemis E, Karanicolas J, Boumber Y. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors. Cellular and Molecular Life Sciences : Cmls. 79: 285. PMID 35532818 DOI: 10.1007/s00018-022-04321-2 |
0.397 |
|
| 2021 |
Topchu I, Karnaukhov N, Mazitova A, Yugai V, Voloshin M, Tikhomirova M, Kit O, Frantsiyants E, Kharin L, Airapetova T, Ratner E, Sabirov A, Abramova Z, Serebriiskii I, Boumber Y, et al. Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC). Journal of Thoracic Disease. 13: 1370-1379. PMID 33841930 DOI: 10.21037/jtd-20-2787 |
0.319 |
|
| 2020 |
Deneka A, Kharin L, Karnaukhov NS, Voloshin M, Ayrapetova TG, Ratner E, Sabirov A, Topchu Y, Mazitova A, Abramova Z, Yugai V, Frantsiyants EM, Kit OI, Boumber Y. Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E21583 |
0.418 |
|
| 2019 |
Bodor JN, Boumber Y, Borghaei H. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). Cancer. PMID 31691957 DOI: 10.1002/Cncr.32468 |
0.374 |
|
| 2019 |
Deneka AY, Boumber Y, Beck T, Golemis EA. Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). Cancers. 11. PMID 31484422 DOI: 10.3390/Cancers11091297 |
0.394 |
|
| 2019 |
Arora S, Velichinskii R, Lesh RW, Ali U, Kubiak M, Bansal P, Borghaei H, Edelman MJ, Boumber Y. Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. Advances in Therapy. PMID 31410780 DOI: 10.1007/S12325-019-01051-Z |
0.367 |
|
| 2019 |
Beck TN, Deneka AY, Chai L, Kanach C, Johal P, Alvarez NJ, Boumber Y, Golemis EA, Laub GW. An improved method of delivering a sclerosing agent for the treatment of malignant pleural effusion. Bmc Cancer. 19: 614. PMID 31234819 DOI: 10.1186/S12885-019-5777-Z |
0.305 |
|
| 2019 |
Beck TN, Boumber YA, Aggarwal C, Pei J, Thrash-Bingham C, Fittipaldi P, Vlasenkova R, Rao C, Borghaei H, Cristofanilli M, Mehra R, Serebriiskii I, Alpaugh RK. Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer. Bmc Cancer. 19: 603. PMID 31215484 DOI: 10.1186/S12885-019-5795-X |
0.39 |
|
| 2019 |
Beck TN, Kudinov AE, Dulaimi E, Boumber Y. Case report: reinitiating pembrolizumab treatment after small bowel perforation Bmc Cancer. 19: 379. PMID 31018834 DOI: 10.1186/S12885-019-5577-5 |
0.359 |
|
| 2019 |
Mamdani H, Chen J, Kim S, Ibrahim Y, Asad MFB, Nieva JJ, Feldman R, Naqash AR, Liu SV, Ma PC, Portnoy DC, Borghaei H, Karim NFA, Boumber Y, Vanderwalde AM, et al. DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 37: 9100-9100. DOI: 10.1200/Jco.2019.37.15_Suppl.9100 |
0.407 |
|
| 2019 |
Kudinov A, Makhov P, Faezov B, Bychkov I, Deneka A, Nicolas E, Caid KQQ, Brebione R, Avrilf E, Nikonova AS, Serebriiskii IG, Borghaei H, Golemis EA, Boumber Y. Abstract 955: Musashi-2 regulates EGFR expression in NSCLC, cell proliferation and survival, response to EGFR inhibitors in EGFR-mutant NSCLC Cancer Research. 79: 955-955. DOI: 10.1158/1538-7445.Am2019-955 |
0.418 |
|
| 2018 |
Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, et al. NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 1171-1182. PMID 30323087 DOI: 10.6004/Jnccn.2018.0079 |
0.373 |
|
| 2018 |
Boumber Y. Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer. Journal of Thoracic Disease. 10: 4689-4693. PMID 30233840 DOI: 10.21037/Jtd.2018.07.120 |
0.371 |
|
| 2018 |
Makhov P, Naito S, Haifler M, Kutikov A, Boumber Y, Uzzo RG, Kolenko VM. The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma. Cell Death and Disease. 9: 374. PMID 29515108 DOI: 10.1038/S41419-018-0388-1 |
0.328 |
|
| 2018 |
Batista L, Brandone N, Garcia S, Boumber Y, Dulaimi E, Tanière P, Hofman P, Ilié M, Adam J, Galon J, Gerbon C, Fieschi J. Abstract 5529: PD-L1 and CD8 IHC dual assessment in NSCLC using the Halioseek® assay: A multicentric study Cancer Research. 78: 5529-5529. DOI: 10.1158/1538-7445.Am2018-5529 |
0.304 |
|
| 2018 |
Makhov P, Kudinov A, Deneka A, Egleston BL, Nicolas E, Cai KQ, Brebion R, Avril E, Hitrik M, Nikonova AS, Serebriiskii IG, Khazak V, Borghaei H, Golemis EA, Boumber Y. Abstract 4452: Musashi-2 regulates EGFR/HER3 expression in NSCLC, cell proliferation and response to EGFR inhibitors in EGFR-mutant NSCLC Cancer Research. 78: 4452-4452. DOI: 10.1158/1538-7445.Am2018-4452 |
0.405 |
|
| 2018 |
Boumber Y, Aggarwal C, Thrash-Bingham C, Fittipaldi P, Guseva P, Vlasenkova R, Rao C, Pei J, Egleston BL, Borghaei H, Cristofanilli M, Mehra R, Serebriiskii I, Alpaugh RK. Abstract 1584: Comparison of circulating tumor cell (CTC) capture/identification methods and NanoString evaluation of gene expression in CTCs and cell-free circulating tumor mRNA (cctmRNA) in patients with metastatic lung cancer Cancer Research. 78: 1584-1584. DOI: 10.1158/1538-7445.Am2018-1584 |
0.452 |
|
| 2017 |
Wahab A, Kesari K, Chaudhary S, Khan M, Khan H, Smith S, Boumber Y. Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation? Cancer Biology & Therapy. 1-4. PMID 29157085 DOI: 10.1080/15384047.2017.1394546 |
0.402 |
|
| 2017 |
Kit OI, Vodolazhsky DI, Kutilin DS, Enin YS, Gevorkyan YA, Zolotukhin PV, Boumber Y, Kharin LV, Panina SB. A Proteomics Analysis Reveals 9 Up-Regulated Proteins Associated with Altered Cell Signaling in Colon Cancer Patients Protein Journal. 36: 513-522. PMID 29128960 DOI: 10.1007/S10930-017-9746-6 |
0.423 |
|
| 2017 |
Boumber Y, Kudinov AE, Karanicolas J, Golemis EA. Musashi RNA-binding proteins as cancer drivers and novel therapeutic targets. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28143872 DOI: 10.1158/1078-0432.Ccr-16-2728 |
0.455 |
|
| 2017 |
Kudinov A, Deneka A, Nikonova AN, Nicolas E, Korobeynikov VA, Serebriiskii IG, Karanicolas J, Golemis EA, Boumber Y. Abstract 3878: Musashi-2 (MSI2) regulation of ERBB family proteins in non-small cell lung cancer (NSCLC) Cancer Research. 77: 3878-3878. DOI: 10.1158/1538-7445.Am2017-3878 |
0.408 |
|
| 2016 |
Bansal P, Osman D, Gan GN, Simon GR, Boumber Y. Recent Advances in Immunotherapy in Metastatic NSCLC. Frontiers in Oncology. 6: 239. PMID 27896216 DOI: 10.3389/Fonc.2016.00239 |
0.403 |
|
| 2016 |
Bansal P, Rusthoven C, Boumber Y, Gan GN. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope. Future Oncology (London, England). PMID 27467543 DOI: 10.2217/Fon-2016-0219 |
0.418 |
|
| 2016 |
Beck TN, Korobeynikov VA, Kudinov AE, Georgopoulos R, Solanki NR, Andrews-Hoke M, Kistner TM, Pépin D, Donahoe PK, Nicolas E, Einarson MB, Zhou Y, Boumber Y, Proia DA, Serebriiskii IG, et al. Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer. Cell Reports. PMID 27396341 DOI: 10.1016/J.Celrep.2016.06.043 |
0.371 |
|
| 2016 |
Kudinov AE, Deneka A, Nikonova AS, Beck TN, Ahn YH, Liu X, Martinez CF, Schultz FA, Reynolds S, Yang DH, Cai KQ, Yaghmour KM, Baker KA, Egleston BL, Nicolas E, ... ... Boumber Y, et al. Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proceedings of the National Academy of Sciences of the United States of America. PMID 27274057 DOI: 10.1073/Pnas.1513616113 |
0.462 |
|
| 2016 |
Gaponova AV, Nikonova A, Deneka AY, Kopp MC, Kudinov AE, Skobeleva N, Khazak V, Shin Ogawa L, Cai KQ, Duncan KE, Duncan JS, Egleston BL, Proia DA, Boumber Y, Golemis EA. A novel HSP90 inhibitor-drug conjugate to SN38 is highly effective in small cell lung cancer (SCLC). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27267850 DOI: 10.1158/1078-0432.Ccr-15-3068 |
0.434 |
|
| 2016 |
Bansal P, Osman D, Gan GN, Simon GR, Boumber Y. Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Frontiers in Oncology. 6: 112. PMID 27200298 DOI: 10.3389/Fonc.2016.00112 |
0.332 |
|
| 2016 |
Rybkin II, Kio EA, Masood A, Shum MK, Halmos B, Blakely CM, Eaton KD, Sharma N, Nemunaitis JJ, Saccaro SJ, Boumber Y, Mena RR, Mirshahidi HR, Janne PA, Christensen J, et al. Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET). Journal of Clinical Oncology. 34: TPS9099-TPS9099. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps9099 |
0.372 |
|
| 2016 |
Beck TN, Korobeynikov V, Kudinov A, Georgeopoulos R, Nicolas E, Einarson MB, Zhou Y, Boumber Y, Proia DA, Serebriiskii IG, Golemis EA. Abstract B25: Anti-Mullerian hormone (AMH) supports epithelial identity and survival signaling in lung cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Fbcr15-B25 |
0.464 |
|
| 2016 |
Kudinov A, Deneka A, Nikonova A, Serebriiskii I, Beck TN, Cai Q, Egleston BL, Nicolas E, Borghaei H, Gibbons D, Kurie J, Golemis EA, Boumber Y. Abstract 1584: Musashi-2 (MSI2) drives TGFBR1/SMAD3 dependent partial EMT and supports VEGFR2 expression and metastasis of human and mouse NSCLC cells Cancer Research. 76: 1584-1584. DOI: 10.1158/1538-7445.Am2016-1584 |
0.481 |
|
| 2015 |
Shih J, Bashir B, Gustafson KS, Andrake M, Dunbrack RL, Goldstein LJ, Boumber Y. Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 947-52. PMID 26285240 DOI: 10.6004/Jnccn.2015.0115 |
0.343 |
|
| 2015 |
Boumber Y, Gaponova A, Nikonova AS, Deneka A, Kudinov A, Egleston BL, Duncan JS, Duncan K, Borghaei H, Mehra R, Proia DA, Golemis E. Preclinical efficacy of STA-12-8666, an HSP90 inhibitor-targeted SN-38 conjugate, in small cell lung cancer (SCLC). Journal of Clinical Oncology. 33: e18560-e18560. DOI: 10.1200/Jco.2015.33.15_Suppl.E18560 |
0.446 |
|
| 2015 |
Kudinov A, Deneka AD, Nikonova A, Ahn Y, Liu XL, Serebriiskii I, Efimov A, Yang D, Andrake MA, Nicolas E, Egleston B, Borghaei H, Gibbons D, Kurie J, Golemis E, ... Boumber Y, et al. Abstract 4098: Musashi-2 (MSI2) activates TGF-β signaling and inhibits CLDN7 to promote non-small cell lung cancer (NSCLC) metastasis Cancer Research. 75: 4098-4098. DOI: 10.1158/1538-7445.Am2015-4098 |
0.473 |
|
| 2015 |
Gaponova A, Nikonova A, Deneka A, Egleston B, Litwin S, Duncan J, Duncan K, Borghaei H, Mehra R, Proia D, Boumber Y, Golemis E. Abstract 1731: Preclinical testing demonstrates strong activity of STA-12-8666, an HSP90 inhibitor-SN-38 conjugate, in small cell lung cancer (SCLC) Cancer Research. 75: 1731-1731. DOI: 10.1158/1538-7445.Am2015-1731 |
0.445 |
|
| 2014 |
Boumber Y, Gaponova A, Nikonova A, Deneka A, Kudinov A, Chikwem A, Egleston B, Litwin S, Duncan J, Duncan K, Borghaei H, Mehra R, Proia D, Golemis E. Preclinical Testing Demonstrates Striking Efficacy of STA-12-8666, an Hsp90 Inhibitor–Targeted SN-38 Conjugate, in Small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 90: S64-S65. DOI: 10.1016/J.Ijrobp.2014.08.287 |
0.411 |
|
| 2013 |
Kuang SQ, Fang Z, Zweidler-McKay PA, Yang H, Wei Y, Gonzalez-Cervantes EA, Boumber Y, Garcia-Manero G. Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia. Plos One. 8: e61807. PMID 23637910 DOI: 10.1371/Journal.Pone.0061807 |
0.467 |
|
| 2013 |
Boumber Y, Kudinov A, Liu X, Ahn Y, Rodriguez J, Wistuba I, Gibbons D, Kurie J. Abstract 2690: The role of musashi-1 in tumor progression in non-small cell lung cancer. Cancer Research. 73: 2690-2690. DOI: 10.1158/1538-7445.Am2013-2690 |
0.482 |
|
| 2012 |
Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 26: 2428-31. PMID 22665218 DOI: 10.1038/Leu.2012.153 |
0.453 |
|
| 2011 |
Konishi K, Watanabe Y, Shen L, Guo Y, Castoro RJ, Kondo K, Chung W, Ahmed S, Jelinek J, Boumber YA, Estecio MR, Maegawa S, Kondo Y, Itoh F, Imawari M, et al. DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis. Plos One. 6: e27889. PMID 22132162 DOI: 10.1371/Journal.Pone.0027889 |
0.55 |
|
| 2011 |
Boumber Y, Younes A, Garcia-Manero G. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor Expert Opinion On Investigational Drugs. 20: 823-829. PMID 21554162 DOI: 10.1517/13543784.2011.577737 |
0.425 |
|
| 2011 |
Boumber Y, Issa JPJ. Epigenetics in cancer: what's the future? Oncology (Williston Park, N.Y.). 25. PMID 21548464 DOI: 10.1016/j.febslet.2011.06.007 |
0.587 |
|
| 2011 |
Boumber Y, Issa J, Jorgensen JL, Faderl S, Castoro RJ, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes JE, Kantarjian HM, Ravandi F. Final Report of a Randomized Study of Decitabine Versus Conventional Care (CC) for Maintenance Therapy in Patients with Intermediate and High Risk Acute Myeloid Leukemia (AML) in First or Subsequent Complete Remission (CR) Blood. 118: 1530-1530. DOI: 10.1182/Blood.V118.21.1530.1530 |
0.502 |
|
| 2010 |
Si J, Boumber YA, Shu J, Qin T, Ahmed S, He R, Jelinek J, Issa JP. Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Research. 70: 6968-77. PMID 20713525 DOI: 10.1158/0008-5472.Can-09-4474 |
0.54 |
|
| 2008 |
Boumber YA, Kondo Y, Chen X, Shen L, Guo Y, Tellez C, Estécio MR, Ahmed S, Issa JP. An Sp1/Sp3 binding polymorphism confers methylation protection. Plos Genetics. 4: e1000162. PMID 18725933 DOI: 10.1371/Journal.Pgen.1000162 |
0.576 |
|
| 2008 |
Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, Gold DL, Sekido Y, Huang TH, Issa JP. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nature Genetics. 40: 741-50. PMID 18488029 DOI: 10.1038/Ng.159 |
0.639 |
|
| 2008 |
Kondo Y, Shen L, Ahmed S, Boumber Y, Sekido Y, Haddad BR, Issa JPJ. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. Plos One. 3. PMID 18446223 DOI: 10.1371/Journal.Pone.0002037 |
0.626 |
|
| 2008 |
Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, Chen X, Vilaythong JN, Issa JP. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Research. 67: 11335-43. PMID 18056460 DOI: 10.1158/0008-5472.Can-07-1502 |
0.625 |
|
| 2007 |
Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, Estey E, Kantarjian H, Garcia-Manero G, Issa JP. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Research. 67: 1997-2005. PMID 17332327 DOI: 10.1158/0008-5472.Can-06-3093 |
0.636 |
|
| 2004 |
Sanchez-Gonzalez B, Hoshino K, Bueso-Ramos C, Yang H, Youssef E, Boumber Y, Santos-Malave C, Garci-Manero G. In Vitro Effects of the Combination of Idarubicin (IDA) with Suberoylanilide Hydroxamic Acid (SAHA) or Valproic Acid (VPA) in Leukemia Cell Lines. Blood. 104: 1173-1173. DOI: 10.1182/Blood.V104.11.1173.1173 |
0.436 |
|
| Show low-probability matches. |